Svoronos Dawn — SEC insider filings
SEC reporting owner CIK 1574579. 30 insider filings on record with FilingPulse; latest filed 2026-09-03.
Transaction summary — filings shown
Covers all 30 filings on record, filed 2020-12-11 to 2026-09-03. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 3 legs across 3 filings — 65,000 shares, $495,916 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 7 legs across 7 filings — 30,636 shares, $1,162,105 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 55.
- Largest priced transaction: sale of 25,000 shares @ $38.70 ($967,500) in Xenon Pharmaceuticals Inc., filed 2023-08-24.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Xenon Pharmaceuticals Inc. (XENE) | Director | 8 | — | 1 leg · 25,000 sh · $967,500 | 13 |
| ACELYRIN, Inc. (SLRN) | Director | 4 | 1 leg · 15,000 sh · $270,000 | — | 10 |
| Adverum Biotechnologies, Inc. (ADVM) | Director | 9 | 2 legs · 50,000 sh · $225,916 | — | 13 |
| Global Blood Therapeutics, Inc. (GBT) | Director | 4 | — | 2 legs · 3,517 sh · $110,776 | 15 |
| PTC THERAPEUTICS, INC. (PTCT) | Director | 5 | — | 4 legs · 2,119 sh · $83,830 | 4 |
Insider filings — Svoronos Dawn
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-03 | 4 | Xenon Pharmaceuticals Inc. (XENE) | Option exercise (M): 5,144 @ $8.15 · Option exercise (M): 5,144 (derivative) @ $0 | EDGAR |
| 2026-06-03 | 4 | Xenon Pharmaceuticals Inc. (XENE) | Option exercise (M): 2,645 · Tax withholding (F): 1,416 @ $53.41 · Option exercise (M): 2,645 (derivative) @ $0 · Grant/award (A): 10,507 (derivative) @ $0 · Grant/award (A): 1,593 (derivative) @ $0 | EDGAR |
| 2025-12-10 | 4 | Adverum Biotechnologies, Inc. (ADVM) | Code (U): 5,000 · Disposition to issuer (D): 4,500 (derivative) · Disposition to issuer (D): 4,000 (derivative) · Disposition to issuer (D): 4,000 (derivative) · Disposition to issuer (D): 4,000 (derivative) · Disposition to issuer (D): 10,520 (derivative) · +1 more | EDGAR |
| 2025-06-20 | 4 | Adverum Biotechnologies, Inc. (ADVM) | Grant/award (A): 10,450 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | Xenon Pharmaceuticals Inc. (XENE) | Grant/award (A): 17,012 (derivative) @ $0 · Grant/award (A): 2,645 (derivative) @ $0 | EDGAR |
| 2025-05-23 | 4 | ACELYRIN, Inc. (SLRN) | Disposition to issuer (D): 15,000 · Disposition to issuer (D): 92,158 (derivative) · Disposition to issuer (D): 23,243 (derivative) · Disposition to issuer (D): 155,450 (derivative) | EDGAR |
| 2024-06-20 | 4 | Adverum Biotechnologies, Inc. (ADVM) | Grant/award (A): 10,520 (derivative) @ $0 | EDGAR |
| 2024-06-11 | 4 | ACELYRIN, Inc. (SLRN) | Grant/award (A): 92,158 (derivative) @ $0 | EDGAR |
| 2024-06-05 | 4 | Xenon Pharmaceuticals Inc. (XENE) | Grant/award (A): 15,542 (derivative) @ $0 | EDGAR |
| 2023-08-24 | 4 | Xenon Pharmaceuticals Inc. (XENE) | Sale (S): 25,000 @ $38.70 | EDGAR |
| 2023-06-13 | 4 | Adverum Biotechnologies, Inc. (ADVM) | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2023-06-02 | 4 | Xenon Pharmaceuticals Inc. (XENE) | Grant/award (A): 18,475 (derivative) @ $0 | EDGAR |
| 2023-05-11 | 4 | ACELYRIN, Inc. (SLRN) | Purchase (P): 15,000 @ $18 · Other (J): 155,450 (derivative) @ $0 · Other (J): 155,450 (derivative) @ $0 · Other (J): 23,243 (derivative) @ $0 · Other (J): 23,243 (derivative) @ $0 | EDGAR |
| 2023-05-04 | 4 | ACELYRIN, Inc. (SLRN) | Grant/award (A): 23,243 (derivative) @ $0 | EDGAR |
| 2022-10-06 | 4 | Global Blood Therapeutics, Inc. (GBT) | Disposition to issuer (D): 5,376 · Disposition to issuer (D): 3,600 (derivative) · Disposition to issuer (D): 30,000 (derivative) · Disposition to issuer (D): 7,500 (derivative) · Disposition to issuer (D): 5,247 (derivative) · Disposition to issuer (D): 5,600 (derivative) · +1 more | EDGAR |
| 2022-06-29 | 4 | Xenon Pharmaceuticals Inc. (XENE) | Grant/award (A): 18,000 (derivative) @ $0 | EDGAR |
| 2022-06-22 | 4 | Global Blood Therapeutics, Inc. (GBT) | Sale (S): 1,908 @ $27.24 | EDGAR |
| 2022-06-16 | 4 | Global Blood Therapeutics, Inc. (GBT) | Option exercise (M): 3,600 · Option exercise (M): 3,600 (derivative) @ $0 · Grant/award (A): 5,600 (derivative) @ $0 · Grant/award (A): 3,600 (derivative) @ $0 | EDGAR |
| 2022-06-14 | 4 | Adverum Biotechnologies, Inc. (ADVM) | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2022-06-10 | 4 | PTC THERAPEUTICS, INC. (PTCT) | Sale (S): 738 @ $27.20 | EDGAR |
| 2022-05-18 | 4 | Adverum Biotechnologies, Inc. (ADVM) | Purchase (P): 30,000 @ $0.85 | EDGAR |
| 2022-01-11 | 4 | PTC THERAPEUTICS, INC. (PTCT) | Sale (S): 510 @ $38.52 · Grant/award (A): 3,200 @ $0 · Grant/award (A): 12,000 (derivative) @ $0 | EDGAR |
| 2021-06-21 | 4 | Global Blood Therapeutics, Inc. (GBT) | Option exercise (M): 3,037 · Sale (S): 1,609 @ $36.54 · Option exercise (M): 3,037 (derivative) @ $0 · Grant/award (A): 5,600 (derivative) @ $0 · Grant/award (A): 3,600 (derivative) @ $0 | EDGAR |
| 2021-06-11 | 4 | PTC THERAPEUTICS, INC. (PTCT) | Sale (S): 365 @ $41.88 | EDGAR |
| 2021-06-03 | 4 | Xenon Pharmaceuticals Inc. (XENE) | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2021-05-14 | 4 | Adverum Biotechnologies, Inc. (ADVM) | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2021-04-01 | 4 | Adverum Biotechnologies, Inc. (ADVM) | Purchase (P): 20,000 @ $10.02 | EDGAR |
| 2021-02-02 | 4 | PTC THERAPEUTICS, INC. (PTCT) | Sale (S): 506 @ $56.96 | EDGAR |
| 2021-01-08 | 4 | PTC THERAPEUTICS, INC. (PTCT) | Grant/award (A): 1,650 @ $0 · Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2020-12-11 | 4 | Adverum Biotechnologies, Inc. (ADVM) | Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-12-09 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1574579 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs